Category: Brandpoint Health

2024-12-18T09:01:00

Your healthcare provider may decrease your dose of TIVDAK, temporarily stop, or completely stop treatment if you have side effects.

What should I tell my healthcare provider before receiving TIVDAK?

Tell your healthcare provider about all your medical conditions, including if you:

• have a history of vision or eye problems
• have numbness or tingling in your hands or feet
• have bleeding problems
• have liver problems
• are pregnant or plan to become pregnant; TIVDAK can harm your unborn baby. Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with TIVDAK
• are breastfeeding (nursing) or plan to breastfeed. It is not known if TIVDAK passes into your breast milk. Do not breastfeed during treatment and for at least 3 weeks after the last dose of TIVDAK

Females who can become pregnant:

• • Your healthcare provider should do a pregnancy test before you start treatment with TIVDAK
  • Use an effective method of birth control during your treatment and for at least 2 months after the last dose of TIVDAK

Males with female partners who can become pregnant:

• • Use effective birth control during treatment and for 4 months after the last dose of TIVDAK

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Taking TIVDAK with certain other medicines may cause side effects.

These are not all of the possible side effects of TIVDAK. Discuss side effects with your healthcare provider. You may report side effects to FDA at 1-800-FDA-1088.

Please see the full Prescribing Information with Medication Guide about TIVDAK including an IMPORTANT WARNING here.

The patient featured in this article is receiving or has received TIVDAK. The patient was compensated by Pfizer/Genmab to share their story. These were their experiences at the time they were interviewed. TIVDAK will not work for everyone. Individual results may vary.

Courtney was compensated for her participation.

Content sponsored and provided by Pfizer and Genmab. Courtney partnered with Pfizer and Genmab to share her experience with recurrent/metastatic cervical cancer.

2024-12-17T09:01:00

(BPT) – When most people think of advanced melanoma treatment, their first thought likely includes chemotherapy, radiation and surgery. Immuno-oncology (IO), also known as immunotherapy, has changed how advanced melanoma can be treated.

Unlike chemotherapy, radiation and surgery, which directly target the tumor, IO uses medication that is designed to leverage the body’s own immune system to help recognize and target tumor cells. IO has the potential to help stop tumor growth or shrink tumors, and it can come in two forms: monotherapy (one immunotherapy) or dual IO (two immunotherapies working together).

Finding an Appropriate Treatment

The first dual IO medication for the first-line treatment of metastatic melanoma (the deadliest form of skin cancer) was approved nearly 10 years ago. Since then, dual IO has become a critical pillar in advanced melanoma treatment. One treatment option in advanced melanoma for adults and children 12 years of age or older is Opdualag™ (nivolumab and relatlimab-rmbw), which is designed to work by connecting to tired T cells and activating them so they can help the immune system attack cancer. All therapies have the potential to result in adverse reactions. See below for Important Safety Information on Opdualag.

Receiving an advanced melanoma diagnosis can be overwhelming, especially if it’s uncharted territory. However, understanding others’ experiences may help patients better navigate a diagnosis.

In 2022, Terry* was diagnosed with metastatic melanoma. As a U.S. veteran, an avid rider of his electric bike and someone who loves to travel and spend time with friends, Terry feared for what this diagnosis meant. He was concerned about the treatment journey ahead. After discussing treatment options with his healthcare team, Terry’s doctor recommended that he receive Opdualag.

Hear more from Terry about his experience and why dual IO was the right treatment for him, as well as expertise from Hussein A. Tawbi, MD, PhD, Melanoma Medical Oncologist, Department of Melanoma Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center,** about navigating an advanced melanoma diagnosis and the importance of continued innovation.

Based on your experience with melanoma, how has your treatment journey impacted your life?

Terry: My diagnosis changed my life.

I’m honored that I was the first patient at the Veterans Affairs (VA) to receive Opdualag after it was approved by the FDA. The results were impactful for me, and treatment was mostly manageable where I experienced a little fatigue, afternoon tiredness, a rash on the back of my neck and a few itchy red blotches on my arm and chest. I’m glad I talked to my doctor about treatment options.

Terry’s results may not be typical. Opdualag may not work for everyone. Individual results may vary.

Why is it important that innovation continues for the treatment of advanced melanoma?

Dr. Tawbi: In the U.S., it is estimated that more than 100,000 new melanomas will be diagnosed in 2024 alone with advanced melanoma representing about 10% of all cases. These statistics stress the urgency for continued scientific innovations, such as dual IO, in cancer treatment.

Based on your personal experience, what would you tell someone who has been diagnosed with melanoma?

Terry: My biggest piece of advice is to find a doctor you trust and can have open and honest conversations with. Together, you and your doctor can develop a personalized treatment plan that you both feel is the right option for you.

Dr. Tawbi, what is your advice for newly diagnosed patients?

Dr. Tawbi: I encourage patients to promptly start a dialogue with their doctor to become more informed about the condition. It’s also important to lean on resources outside of the doctor’s office, such as family, friends and advocacy organizations. The more patients know about their condition, the more empowered they’ll feel to advocate for themselves and engage in treatment decision-making conversations with their doctors.

To learn more about Opdualag, visit www.opdualag.com and speak with your doctor.

*Terry is an actual patient who has been compensated by Bristol Myers Squibb for his role in the article.

**Dr. Tawbi has previously served as a clinical trial investigator and scientific advisor to Bristol Myers Squibb.

INDICATION:

Opdualag™ (nivolumab and relatlimab-rmbw) is a prescription medicine used to treat adults and children 12 years of age or older with a type of skin cancer called melanoma that has spread or cannot be removed by surgery (advanced melanoma). It is not known if Opdualag is safe and effective when used in children younger than 12 years of age or older who weigh less than 88 pounds (40 kg), or in children younger than 12 years of age.

Important Safety Information for Opdualag (nivolumab and relatlimab-rmbw)

What is the most important information I should know about Opdualag?

Opdualag is a medicine that may treat a type of skin cancer called melanoma by working with your immune system. Opdualag can cause your immune system to attack normal organs and tissues in any area of your body and can affect the way they work. These problems can sometimes become severe or can lead to death. These problems may happen anytime during treatment or even after your treatment has ended. You may have more than one of these problems at the same time.

Call or see your healthcare provider right away if you develop any new or worse signs or symptoms, including:

• Lung problems: new or worsening cough; shortness of breath; chest pain
• Intestinal problems: diarrhea (loose stools) or more frequent bowel movements than usual; stools that are black, tarry, sticky, or have blood or mucus; severe stomach-area (abdominal) pain or tenderness
• Liver problems: yellowing of your skin or the whites of your eyes; severe nausea or vomiting; pain on the right side of your stomach area (abdomen); dark urine (tea colored); bleeding or bruising more easily than normal
• Hormone gland problems: headaches that will not go away or unusual headaches; eye sensitivity to light; eye problems; rapid heartbeat; increased sweating; extreme tiredness; weight gain or weight loss; feeling more hungry or thirsty than usual; urinating more often than usual; hair loss; feeling cold; constipation; your voice gets deeper; dizziness or fainting; changes in mood or behavior, such as decreased sex drive, irritability, or forgetfulness
• Kidney problems: decrease in your amount of urine; blood in your urine; swelling in your ankles; loss of appetite
• Skin problems: rash; itching; skin blistering or peeling; painful sores or ulcers in the mouth or nose, throat, or genital area
• Heart Problems: new or worse chest pain; irregular heartbeat or feel like your heart is racing; shortness of breath; tiredness; swelling in your ankles

Problems can also happen in other organs and tissues. These are not all of the signs and symptoms of immune system problems that can happen with Opdualag. Call or see your healthcare provider right away for any new or worsening signs or symptoms, which may include:

• Confusion; sleepiness; memory problems; changes in mood or behavior; stiff neck; balance problems; tingling or numbness of the arms or legs
• Double vision; blurry vision; sensitivity to light; eye pain; changes in eyesight
• Persistent or severe muscle pain or weakness; muscle cramps
• Low red blood cells; bruising

Getting medical help right away may help keep these problems from becoming more serious. Your healthcare team will check you for these problems during treatment with Opdualag. Your healthcare provider may treat you with corticosteroid or hormone replacement medicines. Your healthcare provider may also need to delay or completely stop your treatment with Opdualag if you have severe side effects.

Possible side effects of Opdualag

Opdualag can cause serious side effects, including:

• See “What is the most important information I should know about Opdualag?”
• Severe infusion reactions. Tell your healthcare provider or nurse right away if you get these symptoms during an infusion of Opdualag: chills or shaking; itching or rash; flushing; shortness of breath; dizziness; feel like passing out; fever; back or neck pain
• Complications of stem cell transplant that uses donor stem cells (allogeneic). These complications can be severe and can lead to death. These complications may happen if you underwent transplantation either before or after being treated with Opdualag. Your healthcare provider will monitor you for signs of complications if you have an allogeneic stem cell transplant.

The most common side effects of Opdualag include: muscle and bone pain; tiredness; decreased red blood cell and white blood cell counts; increased liver function test results; rash; itching, diarrhea; decreased salt (sodium) in your blood.

These are not all the possible side effects of Opdualag. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Before receiving Opdualag, tell your healthcare provider if you:

• have immune system problems such as Crohn’s disease, ulcerative colitis, or lupus
• have received an organ transplant
• have received or plan to receive a stem cell transplant that uses donor stem cells (allogeneic)
• have a condition that affects your nervous system, such as myasthenia gravis, or Guillain-Barré syndrome
• are pregnant or plan to become pregnant. Opdualag can harm your unborn baby
  Females who are able to become pregnant:

• your healthcare provider should do a pregnancy test before you start receiving Opdualag
• you should use an effective method of birth control during and for at least 5 months after the last dose of Opdualag. Talk to your healthcare provider about birth control methods that you can use during this time
• tell your healthcare provider right away if you become pregnant during treatment with Opdualag
• are breastfeeding or plan to breastfeed. It is not known if Opdualag passes into your breast milk. Do not breastfeed during treatment with Opdualag and for 5 months after the last dose of Opdualag

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

Please see U.S. Full Prescribing Information and Medication Guide for Opdualag.

© 2024 Bristol-Myers Squibb Company.

Opdualag™ and the related logo are trademarks of Bristol-Myers Squibb Company.

1425-US-2400197 12/24

2024-12-17T09:01:00

(BPT) – In 2024, more than 100,000 people will be diagnosed with melanoma, a form of skin cancer characterized by the uncontrolled growth of pigment-producing cells called melanocytes located in the skin. When melanoma spreads beyond the surface of the skin to other organs (also known as advancing), it can become deadly, which is why it is important to understand the available treatment options if you or a loved one are facing a melanoma diagnosis.

Melanoma is considered the most serious form of skin cancer because it is more likely to spread to other areas of the body. When someone is diagnosed with melanoma, doctors must determine the stage of the cancer, meaning how much the cancer has spread in the body. As melanoma becomes more advanced, meaning it has spread to other organs, it becomes more challenging to treat and survival rates decline. Of patients newly diagnosed with stage I and II melanomas, stage II makes up approximately 16.5%, and approximately half of these are IIB and IIC.

Fortunately, many melanoma patients have treatment options. Surgery, also known as resection, is what most physicians recommend to treat stage IIB or IIC melanoma. However, about one-third of patients with surgically resected stage IIB and nearly one-half of patients with surgically resected stage IIC melanoma experience recurrence (the cancer coming back) within five years after diagnosis. Due to innovations in the melanoma treatment landscape, immunotherapy can be used to treat eligible melanoma patients after surgery. Immunotherapies are designed to use a patient’s own immune system to help prevent the cancer from coming back.

Adjuvant therapy is an additional cancer treatment given after the primary treatment (or surgery for early-stage diagnosis) to help prevent the cancer from coming back. Thanks to treatment innovations, there are adjuvant immunotherapy options for eligible patients that are designed to use a person’s own immune system to help fight their cancer.

In 2023, Opdivo^® (nivolumab) was approved by the U.S. Food and Drug Administration as a prescription medicine used to treat a kind of skin cancer called melanoma. It may be used alone in adults and children 12 years and older with stage IIB, stage IIC, stage III or stage IV melanoma to help prevent melanoma from coming back after it has been completely removed by surgery. This approval provides a treatment option for these melanoma patients that may help prevent their cancer from returning.

Opdivo can cause your immune system to attack normal organs and tissues in any area of your body and can affect the way they work. These problems can sometimes become severe or life-threatening and can lead to death. These problems may happen anytime during treatment or even after your treatment has ended. You may have more than one of these problems at the same time. Serious side effects may include lung problems, intestinal problems, liver problems, hormone gland problems, kidney problems, and skin problems. Call or see your healthcare provider right away if you develop any new or worse signs or symptoms. Please see additional Important Safety Information below.

“Opdivo is a PD-1 inhibitor (a type of immunotherapy) that is indicated as an adjuvant treatment for eligible patients with stages IIB, IIC, III, as well as stage IV completely resected melanoma,” said Hussein A. Tawbi, MD, PhD, Melanoma Medical Oncologist, Department of Melanoma Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center.* “This therapy may help prevent cancer from coming back, providing a treatment option and hope for these patients.”

With the cases of melanoma rising worldwide, it’s important to know and understand the different treatment options available to treat early-stage melanoma that can be removed by surgery. “If you or a loved one has been diagnosed with melanoma, you should speak with your healthcare team about your treatment options based on your specific diagnosis,” said Dr. Tawbi. “Adjuvant treatment options, such as immunotherapy, may be an option.”

If you or a loved one is diagnosed with early-stage melanoma, be sure to ask the healthcare team if Opdivo could be a treatment option after surgery. To learn more about Opdivo, visit Opdivo.com.

*Dr. Tawbi has previously served as a clinical trial investigator and scientific advisor to Bristol Myers Squibb.

INDICATION:

OPDIVO^® (nivolumab) is a prescription medicine used to treat a kind of skin cancer called melanoma. It may be used alone in adults and children 12 years and older with Stage IIB, Stage IIC, Stage III or Stage IV melanoma to help prevent melanoma from coming back after it has been completely removed by surgery.

It is not known if OPDIVO is safe and effective in children younger than 12 years of age with melanoma or MSI-H or dMMR metastatic colorectal cancer.

It is not known if OPDIVO is safe and effective in children for the treatment of any other cancers.

Important Safety Information for OPDIVO^® (nivolumab)

What is the most important information I should know about OPDIVO?

OPDIVO is a medicine that may treat certain cancers by working with your immune system. OPDIVO can cause your immune system to attack normal organs and tissues in any area of your body and can affect the way they work. These problems can sometimes become severe or life-threatening and can lead to death. These problems may happen anytime during treatment or even after your treatment has ended. You may have more than one of these problems at the same time.

Call or see your healthcare provider right away if you develop any new or worse signs or symptoms, including:

• Lung problems: cough; shortness of breath; chest pain
• Intestinal problems: diarrhea (loose stools) or more frequent bowel movements than usual; stools that are black, tarry, sticky, or have blood or mucus; severe stomach-area (abdominal) pain or tenderness
• Liver problems: yellowing of your skin or the whites of your eyes; severe nausea or vomiting; pain on the right side of your stomach area (abdomen); dark urine (tea colored); bleeding or bruising more easily than normal
• Hormone gland problems: headaches that will not go away or unusual headaches; eye sensitivity to light; eye problems; rapid heart beat; increased sweating; extreme tiredness; weight gain or weight loss; feeling more hungry or thirsty than usual; urinating more often than usual; hair loss; feeling cold; constipation; your voice gets deeper; dizziness or fainting; changes in mood or behavior, such as decreased sex drive, irritability, or forgetfulness
• Kidney problems: decrease in your amount of urine; blood in your urine; swelling in your ankles; loss of appetite
• Skin problems: rash; itching; skin blistering or peeling; swollen lymph nodes; painful sores or ulcers in the mouth or nose, throat, or genital area; fever or flu-like symptoms

Problems can also happen in other organs and tissues. These are not all of the signs and symptoms of immune system problems that can happen with OPDIVO. Call or see your healthcare provider right away for any new or worsening signs or symptoms, which may include:

• Chest pain; irregular heart beat; shortness of breath; swelling of ankles
• Confusion; sleepiness; memory problems; changes in mood or behavior; stiff neck; balance problems; tingling or numbness of the arms or legs
• Double vision; blurry vision; sensitivity to light; eye pain; changes in eye sight
• Persistent or severe muscle pain or weakness; muscle cramps
• Low red blood cells; bruising

Getting medical help right away may help keep these problems from becoming more serious. Your healthcare team will check you for these problems during treatment and may treat you with corticosteroid or hormone replacement medicines. Your healthcare team may also need to delay or completely stop your treatment if you have severe side effects.

Possible side effects of OPDIVO

OPDIVO can cause serious side effects, including:

• See “What is the most important information I should know about OPDIVO?”
• Severe infusion reactions. Tell your healthcare team right away if you get these symptoms during an infusion of OPDIVO: chills or shaking; itching or rash; flushing; shortness of breath or wheezing; dizziness; feel like passing out; fever; back or neck pain
• Complications of bone marrow (stem cell) transplant that uses donor stem cells (allogeneic). These complications can be severe and can lead to death. These complications may happen if you underwent transplantation either before or after being treated with OPDIVO. Your healthcare provider will monitor you for these complications.

The most common side effects of OPDIVO, when used alone, include: feeling tired; rash; pain in muscles, bones, and joints; itching; diarrhea; nausea; weakness; cough; vomiting; shortness of breath; constipation; decreased appetite; back pain; upper respiratory tract infection; fever; headache; stomach-area (abdominal) pain; vomiting; and urinary tract infection.

These are not all the possible side effects. For more information, ask your healthcare provider or pharmacist. You are encouraged to report side effects of prescription drugs to the FDA. Call 1-800-FDA-1088.

Before receiving OPDIVO, tell your healthcare provider about all of your medical conditions, including if you:

• have immune system problems such as Crohn’s disease, ulcerative colitis, or lupus
• have received an organ transplant, including corneal transplant
• have received or plan to receive a stem cell transplant that uses donor stem cells (allogeneic)
• have received radiation treatment to your chest area in the past and have received other medicines that are like OPDIVO
• have a condition that affects your nervous system, such as myasthenia gravis or Guillain-Barré syndrome
• are pregnant or plan to become pregnant. OPDIVO can harm your unborn baby.
• are breastfeeding or plan to breastfeed. It is not known if OPDIVO passes into your breast milk. Do not breastfeed during treatment with OPDIVO and for 5 months after the last dose of OPDIVO.

Females who are able to become pregnant:

Your healthcare provider should do a pregnancy test before you start receiving OPDIVO.

• You should use an effective method of birth control during your treatment and for 5 months after the last dose of OPDIVO. Talk to your healthcare provider about birth control methods that you can use during this time.
• Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with OPDIVO.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

Please see U.S. Full Prescribing Information and Medication Guide for OPDIVO.

©2024 Bristol-Myers Squibb Company. OPDIVO^® is a registered trademark of Bristol-Myers Squibb Company.

1506-US-2400473 12/24

2024-12-17T08:01:00

(BPT) – By Brandpoint

Michael was only four years old when he was diagnosed with hemophilia B, a genetic bleeding disorder that affects the body’s ability to generate factor IX, a protein crucial for blood clotting. “It was scary in the beginning,” Michael said. “Kids that age like to copy stuff on TV, and I wanted to play sports or be like Spider-Man. As a preschooler, I really had no idea how to comprehend my diagnosis. And then to learn that I’d have to stick myself with needles multiple times a month made me anxious.”

Hemophilia B causes prolonged bleeding and increases the risk for internal bleeding in the muscles and joints, which can be life threatening if untreated. Missing or insufficient amounts of factor IX can be replaced by medicine to help the body clot properly. The standard treatment for people with hemophilia B involves lifelong, preventative or on-demand factor replacement therapy, which may be infused multiple times a month intravenously (into a person’s veins). However, recent advancements in gene therapy offer new hope.

HEMGENIX^® (etranacogene dezaparvovec-drlb) provides a one-time infusion that can elevate factor IX levels for years, offering greater bleed protection and significantly reducing the need for regular infusions. Michael, who received HEMGENIX, shares his journey with this innovative treatment.

This is Michael’s personal experience. Every patient experience is different. For more information, visit https://www.hemgenix.com.

Q: Before you tried gene therapy, you were on prophylaxis treatment. What was that like?

A: I had to learn to self-infuse prophylaxis from a very early age. Otherwise, I’d have to go to the hospital for treatment anytime I got injured — even from something small like jamming my finger playing basketball.

Once I was consistent with my infusions, I didn’t need to go to the hospital as often, but I still sometimes experienced breakthrough bleeds. I tried not to let hemophilia B hold me back, and I participated in equestrian classes, swimming, basketball and golf, though I had to prepare for activities more than the average kid. I knew if I was going to play basketball, I may get injured, so I would self-infuse before I left the house. I also had to have my medicine with me in case I got hurt or I had to go to the hospital. It was just something I had to deal with.

Q: How did you learn about gene therapy? What motivated you to move forward with treatment?

A: My condition meant I was in and out of the doctor’s office a lot, so I became pretty close to my care team. While I was in college a few years ago, they introduced me to a new treatment option called HEMGENIX.

Around the same time, I had suffered a pretty serious injury, tearing one of my pectoral muscles at the gym. I had to undergo surgery, which was scary because my hemophilia puts me at a higher risk of bleeding during the surgery and recovery. I had to self-infuse more frequently during this time and relied more on my family than ever as an adult. I thought, if there’s a chance to stop sticking myself and help me become more independent, I’ll take it. After discussing my options with my doctor, we decided that HEMGENIX would be a good option for me.

Q: What was receiving gene therapy like?

A: After going through the pre-screening tests and getting approval from my insurance company, I received an infusion date. HEMGENIX was quite new at the time, and there wasn’t a treatment center near my home, so my grandmother and I drove from Louisiana to Mississippi for my infusion. I remember being very excited the entire drive. After having to self-infuse prophylaxis multiple times a month for most of my life, I was hopeful to receive a one-time treatment that could potentially reduce or eliminate my regular infusions for years.

The infusion process took a little over an hour, followed by a few hours of monitoring for infusion-related reactions before I could go home. For me, it was a simple process, and I used the time to get homework and studying done while at the center. Even though I knew what to expect, I still couldn’t believe how easy it was for me.

Q: What’s life like now after your infusion?

A: After receiving HEMGENIX, there were several follow-up appointments I had to do with my doctor, including liver and blood enzyme tests to monitor for any elevations. I also had to watch for any side effects such as headaches, flu-like symptoms, fatigue, nausea, or feeling unwell. Today, my life no longer revolves around my infusion schedule. I haven’t experienced a breakthrough bleed since receiving HEMGENIX and I no longer need regular infusions. I’ve noticed that I feel more confident and less stressed because I know my factor IX levels are steady. I’m not always thinking about if and when I need to infuse. I exercise and play basketball now without having to self-infuse beforehand or afterwards.

I’m currently focused on pursuing my MBA, which I am excited to complete soon. From there, I’m going to pursue a career in business, and I look forward to many of life’s new adventures without the stress of constant infusions.

Q: What message would you like to share with the broader community about living with hemophilia B?

A: I’ve been managing hemophilia B since elementary school and while I tried not to let it stop me from doing the things I wanted, it definitely can be physically and mentally challenging at times. It was always a nagging thought in the back of my head — something I had to constantly consider and be aware of. Having a support system in place is very important.

When my doctor introduced me to HEMGENIX, I was thrilled by the potential benefits but also nervous. Learning all I could about the benefits and risks ultimately helped me make the best decision for myself. However, everyone is different, and needs can change over time, so it’s great that we have so many choices available today. I encourage everyone living with hemophilia B to regularly discuss their treatment options with their doctor to find what works best for them.

What is HEMGENIX?

HEMGENIX^®, etranacogene dezaparvovec-drlb, is a one-time gene therapy for the treatment of adults with hemophilia B who:

• Currently use Factor IX prophylaxis therapy, or
• Have current or historical life-threatening bleeding, or
• Have repeated, serious spontaneous bleeding episodes.

HEMGENIX is administered as a single intravenous infusion and can be administered only once.

What medical testing can I expect to be given before and after administration of HEMGENIX?

To determine your eligibility to receive HEMGENIX, you will be tested for Factor IX inhibitors. If this test result is positive, a retest will be performed 2 weeks later. If both tests are positive for Factor IX inhibitors, your doctor will not administer HEMGENIX to you. If, after administration of HEMGENIX, increased Factor IX activity is not achieved, or bleeding is not controlled, a post-dose test for Factor IX inhibitors will be performed.

HEMGENIX may lead to elevations of liver enzymes in the blood; therefore, ultrasound and other testing will be performed to check on liver health before HEMGENIX can be administered. Following administration of HEMGENIX, your doctor will monitor your liver enzyme levels weekly for at least 3 months. If you have preexisting risk factors for liver cancer, regular liver health testing will continue for 5 years post-administration. Treatment for elevated liver enzymes could include corticosteroids.

What were the most common side effects of HEMGENIX in clinical trials?

In clinical trials for HEMGENIX, the most common side effects reported in more than 5% of patients were liver enzyme elevations, headache, elevated levels of a certain blood enzyme, flu-like symptoms, infusion-related reactions, fatigue, nausea, and feeling unwell. These are not the only side effects possible. Tell your healthcare provider about any side effect you may experience.

What should I watch for during infusion with HEMGENIX?

Your doctor will monitor you for infusion-related reactions during administration of HEMGENIX, as well as for at least 3 hours after the infusion is complete. Symptoms may include chest tightness, headaches, abdominal pain, lightheadedness, flu-like symptoms, shivering, flushing, rash, and elevated blood pressure. If an infusion-related reaction occurs, the doctor may slow or stop the HEMGENIX infusion, resuming at a lower infusion rate once symptoms resolve.

What should I avoid after receiving HEMGENIX?

Small amounts of HEMGENIX may be present in your blood, semen, and other excreted/secreted materials, and it is not known how long this continues. You should not donate blood, organs, tissues, or cells for transplantation after receiving HEMGENIX.

Please see full prescribing information for HEMGENIX.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

You can also report side effects to CSL Behring’s Pharmacovigilance Department at 1-866-915-6958.

HEMGENIX is manufactured by uniQure Inc. and distributed by CSL Behring LLC.

HEMGENIX^® is a registered trademark of CSL Behring LLC.

©2024 CSL Behring LLC 1020 First Avenue, PO Box 61501, King of Prussia, PA 19406-0901 USA

USA-HGX-0907-NOV24

2024-12-16T16:01:01

(BPT) – Like many sisters, 15-year-old Lila and her two sisters share a lot of things, including their love for their family. But unfortunately, all three of them also share the experience of being diagnosed with the same respiratory disorder, which has disrupted their young lives.

To help Lila, her sisters, and many other children with critical illnesses find more joy and hope in their lives, Make-A-Wish helps to grant their wishes — large and small. For Lila and her sisters, they used this opportunity to create lasting memories as they embarked on separate bonding experiences with their parents.

Lila had always wanted to see the West Coast, so when she was told that her wish would be granted, she knew right away that she wanted to go on a special trip to spend time with her mom in Pfeiffer Beach, California.

“Make-A-Wish has been an incredible blessing to our family,” said Lila’s mother Martha. “My daughter dreamed of seeing the West Coast, and it was made into a reality. We experienced so many amazing things — seeing whales and sea lions in the wild, exploring the beautiful California coast, having a day of pampering in a spa — and the list goes on. We were able to forget about the everyday challenges and just enjoy our time together. We will be forever grateful for the gift that Make-A-Wish gave us.”

To make wishes like Lila’s come true, it is imperative to have generous donors and corporate partners like Chase, which joined Make-A-Wish as a national corporate partner in 2024. Because over 80% of wishes involve some form of travel, airfare costs are the greatest expense on travel wishes. In fact, Make-A-Wish would need over 2.8 billion miles to cover every travel wish that they grant each year. To help grant these travel wishes, Chase provided Make-A-Wish with $1.5 million worth of Ultimate Rewards^® points and a $500,000 donation to fuel the travel of wish kids and their families.

How you can make a difference to a child

In addition to Chase’s contribution, Chase Freedom, Sapphire and Ink cardmembers can support Make-A-Wish by donating at Wish.org/Chase, then use Pay Yourself Back to redeem Ultimate Rewards points for the value of the donation after it has posted on their statement. To help cardmembers make an even greater impact, Ultimate Rewards points are worth 25-50% more, depending on which card is used.

You can make a difference for a child like Lila. Unwrap the power of a wish today and help grant life-changing wishes for children with critical illnesses. Visit Wish.org/Chase to learn more.

2024-12-16T09:01:01

(BPT) – It was a day that 6-year-old Abbey and her parents will never forget. Abbey, from San Lorenzo, California, has leukemia. But she got to take some time off from hospitals, treatments and procedures to be a princess, complete with a unicorn companion, just for a day.

When Abbey and her family learned that she would receive a wish from Make-A-Wish^®, she knew her wish right away: Abbey dreamed of traveling to Hawaii to swim in the ocean with dolphins, and to have a tea party with a unicorn. Make-A-Wish Greater Bay Area and local Subaru retailer, Capitol Subaru, were on it. They teamed up to make Abbey’s wish come true. The first step, a princess-themed surprise party to reveal that her wish would soon come true.

They surprised Abbey with presents, a visit from a princess, her favorite snacks and even a “unicorn,” a miniature pony all dressed up for a tea party with Abbey. It made one little girl and her parents very happy, taking their minds off of her illness for a delightful moment in time.

It was an emotional day for Abbey and her family, and for the folks at Capitol Subaru as well. Next would come Hawaii and those dolphins. Abbey and her family left for Abbey’s wish trip of a lifetime on Dec. 1.

“Having a child go through difficult medical treatments is stressful on the entire family,” said Fernando Roque, general sales manager at DGDG’s Capitol Subaru. “We hope that by granting these wishes, we can provide a moment of joy for everyone involved and look forward to continuing to support this great cause.”

According to Make-A-Wish, approximately 27,000 children are diagnosed with a critical illness each year, and research shows that a wish can lead to better health outcomes and a higher chance of survival.

Subaru shares the love

It’s all part of a long-running partnership between Subaru and Make-A-Wish through the Subaru Share the Love^® Event. During the event, which runs from Nov. 21 to Jan. 2 this year, Subaru of America donates $250 for every new Subaru vehicle sold or leased to the customer’s choice of participating charities, including Make-A-Wish.

Since Make-A-Wish has become a participating national charity in the Subaru Share the Love Event, the organization has received more than $35 million in donations, helping to grant more than 3,600 wishes to children fighting critical illnesses in the U.S.

Doing well by doing good

The Subaru Share the Love Event is the textbook definition of doing well by doing good. Subaru is donating a portion from each new Subaru purchased or leased, from now until Jan. 2, 2025, to charities its customers get to designate, including the American Society for the Prevention of Cruelty to Animals^®, Make-A-Wish, Meals on Wheels America and the National Park Foundation. The charities get supported, Subaru customers feel good about the donation and Subaru aligns with what’s most important to its customers. Subaru is the largest automotive or corporate donor to each of those organizations.

There’s a hometown component, too, with local Subaru retailers like Capitol Subaru able to be involved in these lifechanging moments by donating an additional $50 or more to the local charities they’ve partnered with for each new Subaru purchased or leased through Jan. 2.

All of it together is a huge win, a holiday message of kindness and support that everyone involved can feel good about. Especially the unicorn and those dolphins, who had the good fortune of spending a day with a delightful wish kid.

Over the last 16 years of the Subaru Share the Love Event, Subaru and its participating retailers have donated over $288 million to causes around the country and supported nearly 2,300 hometown charities. To learn more, visit: https://wish.org/subaru.

2024-12-16T08:31:00

(BPT) – Expecting mothers have countless preparations to make before their little ones arrive, from decorating the nursery and installing a car seat to picking a pediatrician and thinking about maternal immunizations. For mom and actress Chloe Bridges, who is partnering with Pfizer, navigating pregnancy — and the choices that come along with it — was a little overwhelming.

“Looking back, I was facing so many decisions about how to help protect my baby. Everyone — my friends, my parents, my husband Adam’s parents, social media — had their own opinions,” said Bridges. “It was a lot.”

Now, when reflecting on her pre-birth planning, Bridges says she has ‘new mom clarity.’ One crucial decision she made during pregnancy was receiving ABRYSVO^® (Respiratory Syncytial Virus Vaccine), the only vaccine given to pregnant people at 32 through 36 weeks gestation to help protect infants from the risk of severe respiratory syncytial virus (RSV) from birth through six months.

What is RSV?

RSV is a highly contagious virus that can be dangerous for babies. In fact, RSV is the leading cause of hospitalization in infants in the U.S, with more than 50% of all RSV-related hospitalizations during the first year of life occurring within the first three months, and more than 75% occurring within the first six months.

The role of maternal immunization

During pregnancy, the mother’s body naturally passes antibodies, including those her body creates after receiving a vaccine, to the infant. That means mothers who are between 32 and 36 weeks pregnant can help protect their babies from the risk of RSV starting with their first breath by receiving the ABRYSVO vaccine.

“Expecting mothers are doing everything they can to prepare for the birth of their babies. It’s such a transformative and life-changing experience to have a baby,” said Bridges. “For me, speaking with my OB-GYN throughout my pregnancy journey helped me to make decisions that were right for me and Beau. She answered all my questions and provided me with so much information that I needed to prepare.”

An important maternal vaccine

If you’re pregnant and approaching the third trimester of pregnancy, consider asking your OB-GYN or other healthcare provider about ABRYSVO. Pfizer’s ABRYSVO is the first and only maternal RSV vaccine that helps protect newborns against RSV from birth through six months of age. To avoid the potential risk of preterm birth, ABRYSVO should be given at 32 through 36 weeks gestational age.

The Centers for Disease Control and Prevention (CDC) recommends ABRYSVO if you are 32 through 36 weeks pregnant from September through January (in most parts of the continental United States). Keep in mind that the recommended months for maternal vaccination might vary depending on your location.

Decide what’s best for you and your baby

“I wanted to help protect Beau from RSV from his first breath,” said Bridges. “I’m so glad I decided to get the vaccine for him while I was pregnant.”

Talk to your OBGYN or other healthcare provider to learn more about how to help protect your baby against RSV.

This article was sponsored by Pfizer. To learn more about the vaccine and deepen your knowledge about RSV and maternal immunization, visit ABRYSVO.com.

Important Safety Information and Use

WHAT IS ABRYSVO?

ABRYSVO is a vaccine indicated for pregnant individuals at 32 through 36 weeks gestational age for the prevention of lower respiratory tract disease (LRTD) and severe LRTD caused by respiratory syncytial virus (RSV) in infants from birth through 6 months of age.

• ABRYSVO should not be given to anyone with a history of severe allergic reaction (e.g., anaphylaxis) to any of its components
• To avoid the potential risk of preterm birth, ABRYSVO should be given at 32 through 36 weeks gestational age
• Fainting can happen after getting injectable vaccines, including ABRYSVO. Precautions should be taken to avoid falling and injury due to fainting
• Adults with weakened immune systems, including those receiving medicines that suppress the immune system, may have a reduced immune response to ABRYSVO
• Vaccination with ABRYSVO may not protect all people
• In pregnant individuals, the most common side effects (≥ 10%) were pain at the injection site, headache, muscle pain, and nausea
• In clinical trials where ABRYSVO was compared to placebo, infants born to pregnant individuals experienced low birth weight (5.1% ABRYSVO versus 4.4% placebo) and jaundice (7.2% ABRYSVO versus 6.7% placebo)

Ask your healthcare provider about the risks and benefits of ABRYSVO. Only a healthcare provider can decide if ABRYSVO is right for you. Always talk to your healthcare provider about any side effects you may experience.

You are encouraged to report negative side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Visit http://www.vaers.hhs.gov or call 1-800-822-7967.

Individuals who received ABRYSVO during pregnancy are encouraged to enroll in a pregnancy exposure registry at 1-800-616-3791. The registry will monitor pregnancy outcomes.

Please see full Prescribing Information for ABRYSVO.

PP-A1G-USA-1849 © 2024 Pfizer Inc. All rights reserved. November 2024.

2024-12-13T12:01:00

(BPT) – Diego Serna’s life changed forever in January 2020 when what seemed like a normal Saturday morning playing video games turned into a medical emergency for the then 13-year-old. After a frightening discovery of swollen, painful hands led to a devastating leukemia diagnosis, Diego and his family faced not just one challenge, but a series of them—including a heartbreaking relapse nine months into treatment. For Diego and his family, cancer has been more than a medical journey—it has been a battle that has impacted every aspect of their lives.

While leading-edge medical treatments addressed the disease, it was supportive care at City of Hope that helped Diego and his family navigate their new reality. Through counseling sessions with a psychologist, support from a child life specialist and social worker, and dedicated activities even when isolation was necessary, Diego found ways to cope with his treatment journey. “The supportive care team makes it a little easier,” his father shares. “They help you understand what you’re going through.”

What is Supportive Care?

Supportive care encompasses services that ease the physical, emotional and psychological burdens of cancer. These programs are designed to treat the whole person, not just the disease, which helps patients to focus on their recovery and well-being.

For many, a cancer diagnosis triggers a cascade of worries:

• How do I manage pain?
• Will I ever look like myself again?
• What will happen to me financially?
• How will I explain this to my children?

Supportive care helps address these pressing concerns by offering resources such as pain management, psychological counseling, financial assistance and family support. Research shows supportive care can significantly enhance patient satisfaction and quality of life. Additional health benefits are reduced hospital stays and readmissions and the prevention of complications. The end result: improved overall outcomes.

The Mental Health Perspective

“Cancer doesn’t just impact the body; it profoundly affects the mind and spirit,” says Jeanelle Folbrecht, Ph.D., a psychologist specializing in oncology care at City of Hope’s Los Angeles cancer center. “Supportive care empowers patients to face their fears and uncertainties—whether it’s managing pain, coping with changes in appearance or addressing financial and familial stressors. By tackling these challenges head-on, we help patients build resilience and focus on what matters most in their journey.”

Expanding Access Through National Collaboration

Despite these benefits, fewer than 20% of U.S. cancer patients receive care at National Cancer Institute-designated centers like City of Hope where supportive care is widely available, leaving 80% with inconsistent or limited access to these critical services.

To address these gaps, a coalition of organizations, including City of Hope, is working to make supportive care a standard practice in cancer treatment. Together for Supportive Cancer Care is a national coalition of organizations from across sectors working to support all people with cancer. This effort focuses on improving outcomes and quality of life and lowering the cost of care by expanding early, equitable access to supportive cancer care. Coalition members will be working collaboratively across three focus areas of policy, research and employer support.

The initiative seeks to address inequities and ensure that all patients, regardless of background or location, have access to these vital services. A growing body of evidence shows that supportive cancer care improves patient treatment outcomes and quality of life, while providing higher-value care and lowering long-term health care costs. However, the benefits of supportive care are not currently accessible to everyone with cancer.

A Compassionate Future

Diego’s story underscores the significant difference supportive care can make. Today, he’s back to playing music in a mariachi band—an activity that during treatment seemed impossibly out of reach. As national efforts continue to grow, supportive care is poised to become a cornerstone of cancer treatment—a compassionate approach that puts patients and their families at the center of care, every step of the way.

Photo courtesy “RewritingCancer” / BBC StoryWorks Commercial Productions

2024-12-12T13:31:00

(BPT) – The world’s oceans are a magical, beautiful ecosystem … and they also need help — urgently. According to the Ellen MacArthur Foundation, by 2050, there will be more plastic by weight than fish in the ocean. Let that sink in.

You may have heard of the Great Pacific Garbage Patch — a floating island the size of the state of Texas that is made of debris. And it is growing, in no small part because of how much plastic ends up in the oceans. The amount will boggle your mind. The U.N. Environment Program reports that the equivalent of a dump truck’s worth of plastic is dumped into the oceans every minute of every day. And every one of those plastic bottles will take more than 450 years to decompose.

The enormity of it is hard to get your mind around. If it makes you wonder what you can do about it, you’re not alone.

Plastics are considered to be an essential part of day-to-day life for humans, but overuse threatens the oceans we rely on for survival. It’s called the Blue Paradox. It has grown into a movement to address the global ocean plastic crisis and preserve the environment before it’s too late.

“As plastic waste finds its way to the ocean, it impacts all of us and the vast majority of species on our planet,” said Dr. M. Sanjayan, CEO of Conservation International, a nonprofit dedicated to improving people’s lives by protecting the oceans, forests and other living ecosystems. “The Blue Paradox brings the ubiquitousness and usefulness of plastic and the permanence and scale of its pollution front-and-center, encouraging individuals and businesses alike to take meaningful action.”

SC Johnson, the maker of Windex and other home cleaning brands, is working to turn the tide on ocean plastic waste. To clean up this plastic crisis, it’s not just about individuals being committed to recycling. It’s a collective effort from all of us — individuals, businesses and governments.

The ocean plastic crisis: How you can help

The problem seems daunting, but if everyone does a little, the changes will make a big difference. Here’s what you can do today to help.

Sign the petition. With over 14 million tons of plastic waste dumped in the oceans each year, according to a 2021 report by International Union for the Conservation of Nature, the ocean plastic crisis will not go away on its own, especially when microplastics are in our food chain. Disruptive change is needed, and the solutions can be complex, but we can work together to solve the crisis. Add your voice to this important issue by signing the petition on The Blue Paradox website to help reduce plastic waste.

Sign the pledge. The Blue Paradox website also has a pledge you can take to commit to reducing your plastic footprint. Our actions today can help impact tomorrow. When you sign the pledge, you’ll be kept in the know with information about Blue Paradox’s efforts, and how you’re making a difference.

Take the quiz. Wondering about your own plastic footprint? Here’s a quiz (blueparadox.com/en/plastic-waste-crisis) to let you know for sure. Be honest with your answers, and the quiz will calculate the number of pounds per year you contribute to the plastic landscape.

Reduce your use of single-use plastic where you can. This is easier than you might think. Small, tangible actions such as avoiding single-use plastics like utensils and coffee cups, and swapping out your single-use plastic water bottles for a reusable one, can make a huge difference.

Recycle your plastic. Pop it in the bin! It has never been easier to recycle plastic. Most rigid plastics today are recyclable. One tip: Give yours a quick rinse before tossing it into your recycling bin.

Buy products made from recycled plastic. Industry can do well by doing good … if there’s a market for it. When you’re buying plastic products, look for ones made from recycled plastic. Windex bottles, for example, have been made from 100% post-consumer recycled plastic since 2015. Windex also has the industry’s first bottle made with 100% recovered coastal plastic from a major home cleaning brand. Let’s all work together to create a huge market for products made from recycled plastic and watch how quickly we clean up this problem.

If everyone — including industry — does their part, we can reduce the amount of plastics in our oceans. A little effort today can ensure a more beautiful tomorrow. For more information, visit the Blue Paradox website at https://www.blueparadox.com/.

2024-12-11T16:19:00

(BPT) – This article was sponsored and developed by Neurocrine Biosciences, Inc.

Cerebral palsy (CP) is a neurodevelopmental disorder affecting movement and posture that begins in early childhood development. It is the most common cause of motor disability in children, affecting about one in 345 children in the United States.^1-2 It may happen as a result of lack of oxygen during or around birth, stroke, infection, a problem with metabolism or other problems that cause injury or affect the development of parts of the brain involved in movement control in the first few years of life.³ CP is a permanent condition, affecting a person for their entire life.

People living with CP typically have motor problems, which may include spasticity (abnormal muscle tightness), dyskinesia (uncontrolled movements) or ataxia (poor muscle control), and many people have a mix of these motor disorders.⁴ Dyskinesia due to CP (DCP) is one of the most disabling forms of CP and impacts approximately 10% to 20% of people living with CP.^5-6

According to the Cerebral Palsy Foundation (CPF), the combination of irregular and unpredictable movements (chorea) and twisting and repeating movements (dystonia) often disrupt activities and cause significant functional impairment, including the ability to maintain balance, walk or fine motor control.⁷ Heather Riordan, M.D., Neurologist and Movement Disorders Specialist, Director of the Phelps Center for Cerebral Palsy at the Kennedy Krieger Institute, discusses the symptoms of chorea and impact on patients in a video shared on the CPF website here.

About 30% of people with DCP are affected mostly by these involuntary and irregular movements (chorea), while dystonia is the predominant motor finding in the remaining 70%.⁸ However, it is common for both chorea and dystonia movements to be present together.⁶

For people living with DCP, these movements can occur in any region of the body, including the arms and legs, torso and face and may vary in severity. They are often triggered or made worse by stimulation or stress. Because dyskinesia can occur at rest and/or when actively using the body, the problems with movement are very burdensome in day-to-day living, with discomfort and pain affecting the quality of life for people and their caregivers.⁹

Jen Lyman, mom to a son with DCP, highlights how dyskinesia makes communicating more difficult. “The most difficult thing about dyskinesia is watching my son struggle to do things that he wants to do, but the extra movements get in the way…special things, such as using a touch screen to video chat with his grandmother, are nearly impossible despite his best efforts to use his hands and fingers. Something so simple, yet so special for him should be effortless.”

DCP has a wide-ranging impact on the individual, including lifelong challenges with movement, a higher risk of other medical issues, a higher rate of mental health challenges and difficulties with communication.^10-12

“Those of us who have the privilege to serve patients with dyskinetic, hyperkinetic or mixed cerebral palsy see the functional impact of this very challenging type of tone every day,” said Susan Biffl, M.D., Rehabilitation Medicine Specialist at Rady Children’s Hospital-San Diego and Assistant Professor at UC San Diego School of Medicine. “Patients face challenges with self-care, independence, mobility, communication, fine motor skills that affect occupational and recreational activities, swallowing, social interactions and even sleep. As this tone is variable, it is much more challenging to treat than more consistent tone issues, such as spasticity.”

Treatment Options

There are currently no Food and Drug Administration-approved treatments for DCP. Dystonia and chorea are often managed separately as they respond differently to various treatments, which can make treatment challenging.³ Most drugs being investigated for DCP have focused on dystonia, and more research is needed to determine potential treatments for chorea. New treatment options are needed to help manage these movement disorders and improve daily function and quality of life for those affected.

“After 20 years of caring for individuals with cerebral palsy, I continue to find those with dyskinetic cerebral palsy among the most challenging to treat, largely due to the limited effectiveness of available pharmacologic options,” said Joyce Oleszek, M.D., Professor, Department of Physical Medicine and Rehabilitation, University of Colorado School of Medicine. “There is an urgent need for more robust evidence to support pharmacologic treatments for this condition, given its profound impact on function, comfort and quality of life.”

Ongoing Research

Clinical studies are important in the development of treatment options, allowing researchers to evaluate the safety and effectiveness of new medicines. The data from clinical studies are used to determine if an investigational treatment can be approved for use to treat certain disorders.

There are ongoing clinical studies evaluating potential treatments for DCP, including one for chorea. Neurocrine Biosciences is conducting the KINECT^®-DCP clinical study, a Phase 3, randomized, double-blind placebo-controlled study investigating the study drug, valbenazine, for the treatment of DCP. The clinical study is currently enrolling children, adolescents and adults six to 70 years of age who have been diagnosed with DCP.

“The Cerebral Palsy Foundation is excited to partner with Neurocrine Biosciences on this study,” said Rachel Byrne, Executive Director of the Cerebral Palsy Foundation. “We are proud to support strong research that can potentially bring meaningful change to the lives of those living with cerebral palsy.”

If you or someone you know may be eligible for this research study, please visit the study website for additional information here: FindADCPStudy.com.

REFERENCES

1. Krigger KW. Cerebral palsy: a review. Am Fam Physician. 2006;73(1):91-100.
2. Michael-Asalu A, Taylor G, Campbell H, Lelea LL, Kirby RS. Cerebral palsy: diagnosis, epidemiology, genetics, and clinical update. Adv Pediatr2019;66:189-208. doi:10.1016/j.yapd.2019.04.002
3. Monbaliu E, Himmelmann K, Lin JP, et al. Clinical presentation and management of dyskinetic cerebral palsy. Lancet Neurol. 2017;16(9):741-749. doi:10.1016/S1474-4422(17)30252-1
4. Christine C, Dolk H, Platt MJ, Colver A, Prasauskiene A, Krägeloh-Mann I; SCPE Collaborative Group. Recommendations from the SCPE collaborative group for defining and classifying cerebral palsy. Dev Med Child Neurol Suppl. 2007;109:35-38. doi:10.1111/j.1469-8749.2007.tb12626.x
5. Lumsden DE, Crowe B, Basu A, et al. Pharmacological management of abnormal tone and movement in cerebral palsy. Arch Dis Child. 2019;104(8):775-780. doi:10.1136/archdischild-2018-316309
6. Monbaliu E, de Cock P, Ortibus E, Heyrman L, Klingels K, Feys H. Clinical patterns of dystonia and choreoathetosis in participants with dyskinetic cerebral palsy. Dev Med Child Neurol. 2016;58(2):138-144. doi:10.1111/dmcn.12846
7. Dyskinetic cerebral palsy. Cerebral Palsy Foundation. Published December 20, 2022. Accessed October 29, 2024. https://cpresource.org/understanding-cerebral-palsy/types-cerebral-palsy/dyskinetic-cerebral-palsy
8. Himmelmann K, Hagberg G, Wiklund LM, Eek MN, Uvebrant P. Dyskinetic cerebral palsy: a population-based study of children born between 1991 and 1998. Dev Med Child Neurol. 2007;49(4):246-251. doi:10.1111/j.1469-8749.2007.00246.x
9. Masson R, Pagliano E, Baranello G. Efficacy of oral pharmacological treatments in dyskinetic cerebral palsy: a systematic review. Dev Med Child Neurol. 2017; 59:1237-1248. doi:10.1111/dmcn.13532
10. What is cerebral palsy? Cerebral Palsy Foundation. Accessed November 13, 2024. https://cpresource.org/topic/what-cerebral-palsy
11. Adults & adolescence. Cerebral Palsy Foundation. Accessed November 13, 2024. https://cpresource.org/topic/adults
12. Communication. Cerebral Palsy Foundation. Accessed November 13, 2024. https://cpresource.org/topic/communication

© 2024 Neurocrine Biosciences, Inc. All Rights Reserved. CAP-NBI-US-0115 12/2024
NBI-98854-DCP3018_11DecMatRelease_v1.0_25November2024